Immunitybio News - August 2026

ImmunityBio's second quarter product revenue of $50.7M surges 92%, easily beating estimates, while net loss widens.

ImmunityBio reported second quarter 2026 net product revenue of $50.7 million, a 92% increase year-over-year, marking the eighth consecutive quarter of...

Immunitybio Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026

ImmunityBio is expected to report a Q2 2026 loss of $0.09 per share on revenue of $18.50 million, while the current stock price of $7.45 remains significantly...